Liver Production of Sulfamidase Reverses Peripheral and Ameliorates CNS Pathology in Mucopolysaccharidosis IIIA Mice
Open Access
- 1 February 2012
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 20 (2) , 254-266
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Therapeutic Efficacy of Bone Marrow Transplant, Intracranial AAV-mediated Gene Therapy, or Both in the Mouse Model of MPS IIIBMolecular Therapy, 2010
- Promising CNS-directed enzyme replacement therapy for lysosomal storage diseasesExperimental Neurology, 2009
- Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapyBlood, 2009
- Gene Therapy Using Adeno-Associated Virus VectorsClinical Microbiology Reviews, 2008
- Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis IJournal of Clinical Investigation, 2008
- Mannose 6-Phosphate Receptor–mediated Transport of Sulfamidase Across the Blood–brain Barrier in the Newborn MouseMolecular Therapy, 2008
- Epinephrine enhances lysosomal enzyme delivery across the blood–brain barrier by up-regulation of the mannose 6-phosphate receptorProceedings of the National Academy of Sciences, 2007
- SUMF1 enhances sulfatase activitiesin vivoin five sulfatase deficienciesBiochemical Journal, 2007
- Preclinical Characterization of A Recombinant Adeno-Associated Virus Type 1-Pseudotyped Vector Demonstrates Dose-Dependent Injection Site Inflammation And Dissemination of Vector Genomes to Distant SitesHuman Gene Therapy, 2007
- A fluorimetric enzyme assay for the diagnosis of sanfilippo disease type A (MPS IIIA)Journal of Inherited Metabolic Disease, 1995